Valuation: Shanghai Rendu Biotechnology Co., Ltd.

Market Cap 1.81B 269M 230M 215M 197M 372M 25.76B 376M 2.55B 991M 12.91B 1.01B 988M 42.81B P/E 2024
-179x
P/E 2025 186x
Enterprise Value 992M 148M 126M 118M 108M 204M 14.15B 207M 1.4B 544M 7.09B 555M 543M 23.51B EV / Sales 2024
3.31x
EV / Sales 2025 6.55x
Free-Float
48.41%
Yield 2024
0.56%
Yield 2025 2.38%
05-14 Shanghai Rendu Biotechnology's share trade to resume from May 15 RE
05-13 Nanjing Haijing Pharmaceutical Co., Ltd. agreed to acquire 21.25% stake in Shanghai Rendu Biotechnology Co., Ltd. from Ju Jinliang, Qiming Weichuang Venture Capital Management Company Limited, Runcong Enterprise Management Center (Limited Partnership), China International Capital Corporation Limited, Qiming Ventures Fund III, Changzhou Jinxin Venture Capital Co., Ltd. and Novel Praise Limited for approximately CNY 520 million. CI
05-08 Rendu Biotech's Controlling Shareholder Eyes Share Transfer Deal MT
05-07 Trading in Shanghai Rendu Biotechnology's shares to halt RE
04-28 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-27 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
25-10-30 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-08-29 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-04-29 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-02-27 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-10-29 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
24-08-29 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 CI
24-08-19 Tranche Update on Shanghai Rendu Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 19, 2024. CI
1 day-3.08%
1 week-4.51%
Current month+4.82%
1 month+10.77%
3 months-15.02%
6 months-12.90%
Current year-3.70%
1 week 46.37
Extreme 46.37
50.32
1 month 40.32
Extreme 40.32
50.5
Current year 40
Extreme 40
63.56
1 year 40
Extreme 40
63.56
3 years 22.5
Extreme 22.5
63.56
5 years 22.5
Extreme 22.5
72
10 years 22.5
Extreme 22.5
72
Manager TitleAgeSince
Chief Executive Officer 43 2022-12-08
Chief Tech/Sci/R&D Officer 60 2007-06-12
Director of Finance/CFO 52 2015-07-31
Director TitleAgeSince
Chairman 60 2007-06-12
Director/Board Member 43 2008-04-30
Director/Board Member 61 2020-10-20
Change 5-day change 1-year change 3-year change Capi.($)
-3.08%-4.51%-11.83%+9.99% 277M
-4.40%+3.80%+165.77%+326.61% 22.91B
-0.20%+1.71%-41.64%-23.18% 10.24B
-2.03%+13.75%+346.15%+33.67% 8.48B
-0.53%+19.86%-33.51% - 7.42B
+0.83%-0.15%+73.17%+51.92% 6.53B
-0.77%+0.45%-13.96%-3.00% 6.06B
-4.85%-8.11%+61.51%+99.97% 4.41B
+0.45%+1.42%-13.18%-18.73% 4.34B
-1.50%+1.22%-18.74%-24.87% 2.94B
Average -1.61%+2.98%+51.37%+50.27% 7.36B
Weighted average by Cap. -2.01%+5.91%+89.76%+122.98%

Financials

2024 2025
Net sales 177M 26.42M 22.61M 21.16M 19.34M 36.51M 2.53B 36.95M 250M 97.34M 1.27B 99.21M 97.05M 4.2B 162M 24.13M 20.64M 19.32M 17.66M 33.33M 2.31B 33.74M 229M 88.88M 1.16B 90.59M 88.62M 3.84B
Net income -7.81M -1.16M -996K -932K -852K -1.61M -111M -1.63M -11.03M -4.29M -55.84M -4.37M -4.27M -185M 10.09M 1.5M 1.29M 1.2M 1.1M 2.08M 144M 2.1M 14.24M 5.54M 72.1M 5.64M 5.52M 239M
Net Debt -798M -119M -102M -95.14M -86.97M -164M -11.38B -166M -1.13B -438M -5.7B -446M -436M -18.9B -815M -121M -104M -97.17M -88.82M -168M -11.62B -170M -1.15B -447M -5.82B -456M -446M -19.3B
Logo Shanghai Rendu Biotechnology Co., Ltd.
Shanghai Rendu Biotechnology Co Ltd is a China-based company mainly engaged in the research, development, production, and sales of molecular diagnostic reagents and equipment. The Company mainly operates three businesses. The reagent business is mainly engaged in the research, development, production, and sales of molecular diagnostic reagents for reproductive tract infections, respiratory tract infections, enteroviruses, and bloodborne infectious diseases, as well as other reagent products such as sample preservation solutions and nucleic acid extraction reagents. The instrument business is mainly engaged in the research, development, production, and sales of molecular diagnostic instruments such as the fully automated nucleic acid detection and analysis system (AutoSAT). The testing business is mainly engaged in the provision of clinical testing services, including pathogen detection for the genitourinary system, bloodborne pathogens, respiratory system, and digestive system.
Employees
239
Date Price Change Volume
26-08-24 CN¥46.58 -3.08% 396,174
26-08-21 CN¥48.06 -0.99% 451,164
26-08-20 CN¥48.54 +3.36% 659,141
26-08-19 CN¥46.96 -2.51% 541,939
26-08-18 CN¥48.17 -2.82% 419,321
  1. Stock Market
  2. Stocks
  3. 688193 Stock